Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Equity (2022 - 2025)

Historic Return on Equity for InMed Pharmaceuticals (INM) over the last 4 years, with Q4 2025 value amounting to 0.72%.

  • InMed Pharmaceuticals' Return on Equity rose 3600.0% to 0.72% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.72%, marking a year-over-year increase of 3600.0%. This contributed to the annual value of 0.72% for FY2025, which is 0.0% changed from last year.
  • Per InMed Pharmaceuticals' latest filing, its Return on Equity stood at 0.72% for Q4 2025, which was up 3600.0% from 0.66% recorded in Q3 2025.
  • InMed Pharmaceuticals' 5-year Return on Equity high stood at 0.51% for Q1 2024, and its period low was 5.55% during Q3 2023.
  • For the 4-year period, InMed Pharmaceuticals' Return on Equity averaged around 1.53%, with its median value being 1.08% (2024).
  • In the last 5 years, InMed Pharmaceuticals' Return on Equity crashed by -36400bps in 2023 and then soared by 47700bps in 2024.
  • Quarter analysis of 4 years shows InMed Pharmaceuticals' Return on Equity stood at 1.34% in 2022, then crashed by -197bps to 3.97% in 2023, then skyrocketed by 73bps to 1.08% in 2024, then soared by 33bps to 0.72% in 2025.
  • Its last three reported values are 0.72% in Q4 2025, 0.66% for Q3 2025, and 0.8% during Q2 2025.